The Only Cause of Disease: Healing by Reversing Pathology — Chapter 5 — How Toxins Cause Heart Failure

Chapter 5 — How Toxins Cause Heart Failure

The Only Cause of Disease: Healing by Reversing Pathology — Thomas E. Levy, MD, JD

Part 1 of 7; physical source pages 143–148.

Book introduction and complete contents · Previous section · Next section · Next part

Editorial notice — separate from the source: This is a faithful reproduction of the author’s published source, not an I-OM clinical guideline or endorsement of every claim. It is educational material, not individualized medical advice. The source’s original disclaimers and copyright notices are retained. Safety note: Do not use this reproduction as instructions for self-treatment. Hydrogen peroxide mist can irritate the respiratory tract; higher exposures can cause serious lung injury. See CDC/ATSDR safety guidance.

Unchanged original PDF


Source page 143

Open original page 143 — full-size image

Chapter 5 A man dies when he refuses to take a stand for that which is true. Martin Luther King, Jr.

How Toxins Cause Heart Failure

General Heart Assessment Cardiomyopathy, which simply means heart muscle disease, can occur as a primary affliction of the heart muscle, as a secondary condition negatively impacting heart function, or as a combination of both. 1-3 Heart failure is a clinical diagnosis that describes the severity of limitations in cardiac output, or the amount of blood the heart is capable of pumping. For the practicing clinician, the most critical considerations in approaching the cardiomyopathy patient with clinical heart failure are: ✓ Is the heart muscle itself diseased? ✓ Is the heart muscle normal, but being forced into failure by non-cardiac factors? ✓ Is the clinical presentation a combination of both these conditions? ✓ Is the treatment protocol aimed only at relieving symptoms or also at resolving the underlying pathology resulting in clinical heart failure? 143

Source page 144

Open original page 144 — full-size image

144 THE ONLY CAUSE OF DISEASE

Because cardiomyopathy presenting in clinical heart failure is a condition often involving multiple factors, there is no single treatment protocol that can be considered optimal. Furthermore, heart failure rarely occurs in isolation without other diseases and co-morbid conditions being present and contributing to its symptoms as well. 4-5 However, all presentations of heart failure share features that must be addressed, regardless of whatever other treatments are being administered. The enormous public health impact of heart failure cannot be overstated. In Germany, for example, heart failure is the most common primary inpatient diagnosis. 6

Heart Failure Pathophysiology When the function of the heart is impaired sufficiently to decrease the amount of blood that should be pumped with every heartbeat (cardiac output), a clinical picture of heart failure will eventually emerge. As the body can clinically compensate reason- ably well for early heart failure, it is only when the decreased function is severe enough and chronic enough that heart failure symptoms become clear-cut. Because of this, even seemingly mild heart failure symptoms should be taken very seriously, with a complete diagnosis (especially in the ongoing pandemic setting), and the application of scientifically based treatments to support and improve heart function. Common symptoms of heart failure include the following, due basically to the abnormal accumulation of fluid in the lungs and the rest of the body from inadequate heart pumping ability: 7-8 ✓ Shortness of breath at rest or too quickly with exertion ✓ Shortness of breath when lying flat ✓ Waking up suddenly short of breath ✓ Fatigue

Source page 145

Open original page 145 — full-size image

How Introduction Toxins Cause Heart Failure 145

✓ Swelling in feet, ankles, and eventually legs and/or abdomen ✓ Accelerated heart rate, palpitations ✓ Heart muscle cells do not just fail and “wear out” for no reason. When oxidative stress increases within heart cells (myocytes), inflammation, by definition, also exists there. Additionally, part of the increased oxidative stress is attributed to a decrease in ATP (adenosine triphosphate) production in the mitochondria of heart cells. As ATP is the primary energy-providing molecule in the body, heart cells with compromised ATP production experience increased oxidative stress, resulting in a clinical picture of inflammation, or myocarditis. When the factors increasing oxidative stress are intense and acute in onset, rapid heart enlargement with poor heart contraction (congestive cardiomyopathy) will result. However, when the factors increasing oxidative stress are less intense and more chronic, the heart will generally first “adapt” by increasing the heart wall thick- ness without enlargement of the left ventricular dimensions (hyper- trophic cardiomyopathy). A clinical picture of heart failure will still be present and continue to evolve as the heart wall thickens, making the left ventricle stiffer and less compliant. This results in the heart chamber not filling up as readily (diastolic heart failure, or heart failure with preserved ejection fraction) 9-10 Effectively, this form of cardiomyopathy consumes more ATP trying to fill the heart than it does to pump and empty it. 11 With this resistance to heart chamber filling, the amount of blood pumped with each heartbeat eventually decreases, and the blood supply coming into that chamber “backs up,” resulting in the heart failure symptoms noted above. To be discussed below, toxins cause both forms of cardiomyopathy. Left untreated, the terminal stages of hypertrophic cardiomyopathy evolve into a congestive cardiomyopathy, with substantial enlargement of the

Source page 146

Open original page 146 — full-size image

146 THE ONLY CAUSE OF DISEASE

left ventricle and very poor contractility. This will result even when the heart was not enlarged or poorly contracting at the onset of the myocardial inflammation. The initial clinical presentation of heart failure is roughly split equally between hypertrophic and congestive cardiomyopathy. 12 Loss of functioning heart muscle is commonly considered to be the cause of congestive cardiomyopathy most of the time. This is undoubtedly a major reason for heart failure when multiple heart attacks with death of heart muscle and fibrotic scarring are present in place ...toxins cause of contracting heart muscle. However, both forms of heart biopsies in consecutive patients with advanced coronary artery block- cardiomyopathy. ages and clinical heart failure indi- Left untreated, the cated otherwise. The microscopic terminal stages evaluation of these biopsies indi- of hypertrophic cated that myocarditis (heart muscle cardiomyopathy inflammation) was the underlying evolve into cause, and heart function in some of these patients improved dramatically a congestive with anti-inflammatory measures. In cardiomyopathy, the absence of active ischemia or old with substantial heart attacks with extensive loss of enlargement of heart tissue, it is erroneous to consider the left ventricle ischemia as a primary cause of conges- and very poor tive heart failure, except to the degree that it increases oxidative stress in the contractility. remaining heart muscle. The crucial takeaway point is that myocarditis is not necessarily an obvious diagnosis. There must be a lower threshold for taking heart tissue biopsies, as missing the diagnosis of a treatable condition greatly increases morbidity and mortality for many patients. 13

Source page 147

Open original page 147 — full-size image

How Introduction Toxins Cause Heart Failure 147

Toxins and the Heart While toxin accumulation in the heart muscle can be the singular cause of advanced heart failure, it will much more often be one of several factors contributing to decreased heart contrac- tility and function. Also, the chronicity of heart failure, regardless of cause, will play a significant role in determining its reversibility, as more inflamed heart cells will eventually die. As cells die, the loss of function is more permanent and not just related to how well chronically inflamed cells can subsequently recover. Such inflamma- tion is consistently seen on the microscopic study of heart biopsies in toxin- and infection-related cardiomyopathy. 14-15 Various toxins, including many heavy metals, have been either linked to heart failure or clearly shown to be the direct cause. Heavy metals significantly increase oxidative stress and promote disease wherever they accumu- late. 16-21 Furthermore, one or more of these heavy metals are nearly always present in high concentrations in the poorly contracting heart muscle. A partial list of such agents includes the following: ✓ Lead ✓ Copper ✓ Iron ✓ Mercury ✓ Aluminum ✓ Cobalt/Chromium ✓ Cadmium ✓ Gold/Silver ✓ Chemotherapy ✓ COVID Spike protein

Lead: In a 3-year-old girl with chronic lead poisoning, acute heart failure developed that was clinically reversed after four days of

Source page 148

Open original page 148 — full-size image

148 THE ONLY CAUSE OF DISEASE

calcium EDTA chelation therapy. 22 Children who died from heart failure secondary to acute lead poisoning were documented to have the microscopic findings of myocarditis. 23 Lead has been shown in other studies to target the heart and the vascular system. 24-27 Animal studies have also shown that enough lead exposure will reliably cause myocarditis and vascular damage, as is seen in humans. These studies demonstrate that lead exposure can promote atherosclerosis and high blood pressure as well. 28-30

Copper: A transition metal necessary for normal cell function but easily pushed to excess and toxic levels in the body, copper is another culprit toxin commonly involved in cardiomyopathy patients. 31 Excess copper appears to be espe- cially toxic to the heart, as the infusion of copper into the coronary circu- ...a clear diagnosis lation of rats results in impaired of copper excess heart function in only minutes. 32 does not need to Hypertrophic cardiomyopathy has been strongly linked to the excess be made before copper levels seen in Wilson’s disease. treating patients Trientine, a selective copper chelator, presumptively as has been shown to improve cardiac having too much function in patients with hypertrophic cardiomyopathy. 33 copper in their In a randomized, placebo-con- heart, especially when trolled trial of diabetic patients with heart wall thickening left ventricular thickening (which can is present in a lead to hypertrophic cardiomyop- diabetic patient. athy), copper chelation significantly decreased heart wall thickening. This study did not even screen for elevated copper levels. 34-35 Furthermore, trientine chelation in diabetic rats with advanced left ventricular failure over an eight-week period demonstrated significantly improved heart function. 36 Another


Book introduction and complete contents · Previous section · Next section · Next part

Chapter 5 — How Toxins Cause Heart Failure

The Only Cause of Disease: Healing by Reversing Pathology — Thomas E. Levy, MD, JD

Part 2 of 7; physical source pages 149–154.

Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Unchanged original PDF


Source page 149

Open original page 149 — full-size image

How Introduction Toxins Cause Heart Failure 149

study on heavy metal removal in diabetic rats, using either trientine or citrate (citric acid), significantly protected heart function. 37 In a case report, a patient with scleroderma and a congestive cardiomy- opathy improved dramatically on penicillamine, an effective chelator of copper, lead, and mercury. No copper level testing was reported as part of the patient’s evaluation. 38 These studies further indicate that toxicity from copper and/or other heavy metals in the heart is a common and significant contributing factor in patients with early heart wall thickening and then its later decompensation into decreased cardiac function and heart failure. It appears that a clear diagnosis of copper excess does not need to be made before treating patients presumptively as having too much copper in their heart, especially when heart wall thick- ening is present in a diabetic patient. 39 It has also been shown that a copper-overload state is a primary factor in the pathogenesis of damage to any organ in the diabetic. 40 Copper removal has also been shown to decrease the inflammatory response to radiofrequency ablation treatment for liver cancer in rats. 41 These findings strongly suggest that:

The unsuspected presence of excess copper in tissues and organs can impair the resolution of any pathol- ogy being treated, suggesting a potential beneficial role for copper removal measures for various medi- cal conditions.

Iron: Congestive heart failure secondary to severe iron overload in the body has been reported. The daily administration of an iron chelator (deferoxamine) to a patient with congestive cardiomyop- athy over approximately a year resulted in a significant improve- ment in heart function and cardiac output, with the heart’s pumping ability more than doubling (ejection fraction increased from 20% to 48%). 42 Another case report described a 27-year-old

Source page 150

Open original page 150 — full-size image

150 THE ONLY CAUSE OF DISEASE

woman with “severe heart failure” who completely normalized on an iron removal regimen. 43 Patients with severe iron overload cardiomyopathy have an average survival of only one year when therapeutic phlebotomy (blood donation) and iron chelation are not utilized. This In animal studies, form of cardiomyopathy begins with excess cellular iron restricted filling of the heart (diastolic in heart cells has dysfunction) and then progresses to been shown to congestive cardiomyopathy. 44 increase oxidative Iron overload cardiomyopathy occurs stress and impair most commonly in patients with heredi- tary hemochromatosis or secondary hemo- the mitochondrial chromatosis (as with β-thalassemia and electron transport sickle cell anemia). 45 However, excess iron chain’s (ETC) short of that seen in full-blown hemo- ability to produce chromatosis can still be expected to inflict ATP. its dose-dependent toxicity. Most adults already have excess levels of iron in their bodies, as indicated by elevated ferritin levels that are often erroneously considered normal in laboratory reference ranges. Excess iron in the heart is also a predisposing factor to developing atrial fibrillation, an arrhythmia that contrib- utes to increased morbidity and mortality. 46 In animal studies, excess cellular iron in heart cells has been shown to increase oxidative stress and impair the mitochon- drial electron transport chain’s (ETC) ability to produce ATP. As ATP is the primary energy-providing molecule in the body, any decrease in its production always results in compromised cellular function. 47-48 Notably, resveratrol supplementation has been shown to dramatically improve heart function in animal models of iron overload cardiomyopathy. 49-51 In another animal study, either deferiprone or N-acetylcysteine was effective in decreasing cardiac iron concentration. 52

Source page 151

Open original page 151 — full-size image

How Introduction Toxins Cause Heart Failure 151

Mercury: As the most toxic non-radioactive element, mercury is a heavy metal that causes grave damage wherever it accumulates. A landmark study directly compared toxic heavy metal concentra- tions in biopsies of heart muscle in patients with idiopathic dilated cardiomyopathy (IDCM) against control muscle biopsies. IDCM is a condition of advanced heart failure with a very enlarged heart of unknown cause. The cardiomyopathic heart muscle contained 22,000 times more mercury than normal heart muscle. In compar- ison to normal specimens, the same diseased heart muscle contained 12,000 times more antimony, 11 times more gold, 13 times more chromium, and 4 times more cobalt. Notably, the study group did not undergo primary screening to detect increased heavy metal exposure, suggesting that these accumulations likely repre- sent the findings in most cases of IDCM. 53 Unless excess exposures to heavy metals are readily apparent, the widespread effects of such poisonings make it very unlikely that such a toxicity will be suspected and then correctly diagnosed. 54 Heavy metal exposure, with mercury exposure of most significant consequence, has been shown to increase the risk for severe congenital heart defects in the offspring. 55 In another study, the heart muscle of patients with cardiomyop- The cardiomyopathic athy examined at autopsy was found heart muscle to have significantly higher levels of contained 22,000 lead, nickel, copper, and manganese, times more mercury as well as significantly lower levels than normal of zinc, compared to the heart muscle heart muscle. of patients without cardiomyopathy. Mercury and antimony levels were not reported and were presumably not measured. 56 This study indicates that most patients with IDCM have not only astronomical levels of mercury and antimony but also significant elevations of lead,

Source page 152

Open original page 152 — full-size image

152 THE ONLY CAUSE OF DISEASE

nickel, and copper. If it were not a vital organ, the heart’s ability to selectively remove heavy metals from the blood and the rest of the body could be considered a protective mechanism for the body’s health. This leads to the conclusion that:

Cardiac muscle in patients with advanced congestive cardiomyopathy is the preferred site for the accumu- lation of most heavy metals that enter the body.

Currently, IDCM is the cause of heart failure in over 100,000 people in the United States, and it is the underlying diagnosis leading to 45% of heart transplants. Furthermore, evidence of resolved or ongoing viral infection in heart biopsy specimens is seen in 25% of IDCM patients. 57 Up to 80% of IDCM patients demonstrate one or more anti-heart autoantibodies. Such anti- bodies are commonly the result of occult infections. Heavy metal accumulations and chronic viral myocar- ditis appear to be pathology-precipitating ...it appears that partners. 58 While it is unclear whether heavy metal one factor better facilitates the presence accumulation, of the other, it appears that heavy metal accumulation, headed by mercury and headed by probably antimony, is a prevalent cause mercury and of IDCM. Based on these studies that have probably specifically measured heavy metal status antimony, is a in IDCM heart muscle, heavy metal accu- prevalent cause mulation appears to be the culprit for this advanced form of heart failure most of the of IDCM. time. The IDCM heart seems to be a chem- ically attractive site for the accumulation of multiple heavy metals after being primed by an earlier myocardi- tis-precipitating viral infection, as no other organ in the bodies of IDCM patients appears to concentrate these toxins similarly.

Source page 153

Open original page 153 — full-size image

How Introduction Toxins Cause Heart Failure 153

Mercury also works effectively to produce a deficiency state of selenium. Restoring deficient selenium stores can lessen clinical mercury toxicity, although it does not directly promote the mobilization or elimination of mercury. Congestive cardiomy- opathy secondary to selenium deficiency has been reported, and restoring depleted selenium levels can reverse it. 59-62 Based on the data above on mercury and IDCM, a cardiomyopathy associated with selenium deficiency is likely a cardiomyopathy significantly worsened by the toxicity of excess mercury, no longer negated by a sufficient presence of selenium. Notably, excessive supplemental selenium can be toxic, unlike many other nutrient supplements, and should not be overused.

Aluminum: Aluminum phosphide, an agent used as a pesticide, induced a severe, but reversible, cardiomyopathy after accidental poisoning in an exterminator. 63 Intense supportive care to reverse low blood pressure was shown to facilitate the recovery of other individ- uals poisoned with aluminum phosphide, that resulted in severe compromise of heart contractility. 64-65 In a hemodialysis patient who expired with heart failure, heavy aluminum deposits were seen in the heart cells upon electron microscope examination. 66 An animal study also showed that aluminum chloride could induce a largely reversible cardiomyopathy. 67 Organic acids (succinic, malic, or citric) and the iron chelator, desferrioxamine, are agents that can mobilize (solubilize) and eliminate aluminum accumulations. 68

Cobalt/Chromium: Cobalt is another toxic heavy metal documented as a cause of congestive cardiomyopathy. Elevated blood cobalt levels have been identified in some patients with metal hip implants. 69-70 Elevated blood chromium levels from the implants have also been

Source page 154

Open original page 154 — full-size image

154 THE ONLY CAUSE OF DISEASE

observed. 71-72 However, the presence of such elevations does not guarantee that a cardiomyopathy will result. 73 As noted above, IDCM often starts with an undiagnosed viral myocarditis. Such a myocarditis appears to inflict the myocardial damage that triggers the almost sponge-like uptake of cobalt and other heavy metals, as described in the section on mercury accumulation in the heart. An animal study also showed that a poor diet (protein restriction) further predisposed the heart to cobalt toxicity. 74 N-acetylcysteine is effective in significantly reducing the blood concentrations of both cobalt and chromium. 75 Alpha lipoic acid is another effective chelator of cobalt. 76

Cadmium: A study examining blood, serum, and urine heavy metal levels found significantly higher cadmium levels in patients with IDCM compared to healthy controls. 77

Gold/Silver: While gold and silver are not generally recognized as toxic substances, some care must always be exercised in a supplemen- tation regimen, especially one involving metals. In a case report, a dilated congestive cardiomyopathy resulted from the excessive ingestion of colloidal gold for about three months, along with a history of intermittent colloidal silver ingestion over the prior seven years. In addition to an enlarged heart that was contracting poorly, a significant new heart conduction abnormality (left bundle branch block) resulted from this supplementation. Following chelation therapy (dimercaprol), the block disappeared, and the heart’s ejection fraction improved from 20% to 50%, a very dramatic improvement. Notably, urine screening (with no tissue levels measured) revealed no evidence of excess aluminum, arsenic, barium, beryllium, cadmium, copper, manganese, or thallium. 78


Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Chapter 5 — How Toxins Cause Heart Failure

The Only Cause of Disease: Healing by Reversing Pathology — Thomas E. Levy, MD, JD

Part 3 of 7; physical source pages 155–160.

Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Unchanged original PDF


Source page 155

Open original page 155 — full-size image

How Introduction Toxins Cause Heart Failure 155

Chemotherapy: Cancer chemotherapy utilizes some agents that are highly toxic to the heart. Anthracyclines (doxorubicin, idarubicin, epirubicin, and mitoxantrone) often result in some degree of heart enlarge- ment and decreased contractility. 79-80 These are cardiac effects that are largely considered irreversible, despite chelation therapy being effective in preventing such cardiac damage. 81-84 Considering that multiple toxins and heavy metals are typically present in patients with IDCM, it should not be assumed that trying to remove as much of the toxin load from the body (and the heart) will be of no benefit. Cancer patients typically have other diseases as well, and it is reasonable to think that some of these patients (such as those with the copper accumulation often seen in diabetes) might have already been accumulating cardiac toxins long before there was any evidence of cardiac compromise. As such, chelation therapy would have the potential to reverse the cardiac damage currently seen with chemotherapy at least partially.

COVID Spike Protein: Persistent spike protein (PSP) syndrome is seen when the COVID-19 pathogen-related spike protein stays in the body following a COVID vaccination and/or because it was never elim- inated following an unresolved COVID infection (chronic or long-haul COVID). 85-87 While the spike protein has been detected throughout the body in autopsy studies of COVID-19 patients, it appears to have a particular predilection for targeting the heart and its blood vessels. 88-93 The spike protein inflicts damage in the heart and elsewhere in the body by multiple mechanisms. These mechanisms include: ✓ Facilitating COVID pathogen entry into cells (ACE2 receptor binding) 94-96

Source page 156

Open original page 156 — full-size image

156 THE ONLY CAUSE OF DISEASE

✓ Overstimulation of the immune response due to chronic activation by the continual presence of PSP potentially leads to the development of an autoimmune disease 97-99 ✓ Attacking not only tissue and organ cells directly, but also the walls of the blood vessels and the platelets circulating in them, resulting in the increased formation of blood clots 100-101 ✓ Intrinsic toxicity of both the complete spike protein and its fragments 102-104 ✓ The ability to enter the genome of the cell, where it cannot be readily eradicated, along with the seeming ability to be replicated indefinitely 105 Myocarditis, sometimes involving heart enlargement and heart failure, can result from the spike A heart with a protein exposure following COVID-19 vaccine(s) and/or from its persistence in minimal elevation chronic COVID. However, many cases of troponin is the of spike protein myocarditis, probably a perfect setting substantial majority, are chronic, smol- for a catastrophic dering conditions that remain undiag- clinical response nosed except when there is clear clinical evidence indicating their presence. when an additional Myocarditis, which means inflam- spike protein-laden mation of some or all the muscle cells injection is given, in the heart, can occur when the spike much like what protein binds to the blood vessels in the gasoline would do heart, to the muscle cells themselves, or to smoldering coals. both. 106 Even when the myocardial blood vessels get more selectively targeted, inflammation of the heart muscle itself can still eventually ensue as the circulation of the heart becomes progressively impaired by blood clotting and/or by an increased resistance to blood flow resulting from inflammation-induced

Source page 157

Open original page 157 — full-size image

How Introduction Toxins Cause Heart Failure 157

vasoconstriction. Pre-pandemic myocarditis (cases not related to a spike protein presence) generally did not involve any predisposition to blood clotting in addition to the inflammation of the affected heart muscle cells. Myocarditis offers no significant diagnostic challenge when it presents in its classical manner. Chest pain and rapid heart rate are often the earliest symptoms. If the myocardial inflammation is evolving rapidly, symptoms of congestive heart failure, including shortness of breath and swelling of the lower legs, can occur as well. Not uncommonly, an upper respiratory tract viral infection will be present, or there will be a history of such an infection having recently resolved clinically. Chest X-ray, electrocardiogram (ECG), and echocardiogram can all be used to help establish the diagnosis. An elevated troponin level on blood testing is extremely sensitive in detecting ongoing heart muscle cell damage, and some elevation of this test will always be seen if significant inflammation is present in a large enough number of heart muscle cells.

Any continued elevation of troponin in the blood, however minimal, must be regarded with significant concern, even if there appears to be a complete clin- ical resolution of the myocarditis. Everyone should have this test done, even if they are feeling perfectly well, to both establish a baseline within the normal range and to detect any unsuspected low-grade myo- cardial inflammation.

The very high sensitivity of the troponin test has revealed that there are countless numbers of people post-COVID infection and/ or post-vaccination who are continuing to have sustained subclin- ical degrees of myocardial inflammation. No matter how minimal the elevation of the test, any increase means that a gradual and continued loss of heart muscle function will occur over time. It also means that the heart is highly susceptible to an acute and potentially severe worsening of heart function when an additional

Source page 158

Open original page 158 — full-size image

158 THE ONLY CAUSE OF DISEASE

exposure to more spike protein occurs, as has been seen with the vigorously promoted booster shots.

A heart with a minimal elevation of troponin is the perfect setting for a catastrophic clinical response when an additional spike protein-laden injection is given, much like what gasoline would do to smolder- ing coals. Not surprisingly, it has been shown that COVID patients with higher troponin levels were more likely to die than those with lower levels. 107

Many abnormal troponin tests eventually resolve completely, and many do not. The quality of the diet and its proper digestion, the strength of the immune system, and the quality of the nutrient/ vitamin/mineral supplementation being taken are all critical factors in determining whether a minimal, subclinical degree of inflam- mation in the heart is capable of completely resolving with a return of the troponin level into the reference, or normal, range. With much of the world consuming a poor diet and not supplementing, there is an ongoing presence of spike protein in a large number of people worldwide. Clinical myocarditis is an advanced state of heart inflammation, characterized by significantly higher levels of troponin being released into the bloodstream. Cardiac injury was detected in 20% to 40% of patients hospitalized with COVID. 108-109 Any troponin elevation in hospitalized COVID patients was associ- ated with increased mortality. 110 Troponin testing is currently the most important and widely accepted method for determining whether a suspected heart attack has occurred, as troponin is released into the circulation when heart muscle cells die. 111 Some degree of myocardial injury is felt to be present when any troponin level is detected beyond the 99th percentile upper reference limit, whether in the context of a suspected heart attack or the possible presence of any inflammation in the heart. 112-113 Even an increase in baseline troponin levels that remains below the established upper limits of normal (or reference

Source page 159

Open original page 159 — full-size image

How Introduction Toxins Cause Heart Failure 159

range) is significantly associated with increased mortality after noncardiac surgery. 114 Baseline troponin testing is a good idea for everyone, since normal ranges can vary from lab to lab, and because it appears myocardial injury can still be present when the troponin level rises significantly from a baseline Compared to point but remains short of the upper patients with no reference limit. 115 troponin elevation, a significant The importance of the most minimal troponin elevations has increase in 30-day been established in several studies mortality was seen examining the relationship between in patients having preoperative troponin levels and long- minor troponin term mortality following noncardiac elevations following surgery. Compared to patients with noncardiac surgery. no troponin elevation, a significant increase in 30-day mortality was seen in patients having minor troponin elevations following noncardiac surgery. 116-117 Another similar study found greater than a doubling of the mortality rate when the two patient groups were evaluated at three years following the noncardiac surgery. 118 Furthermore, these increases in mortality were observed in patients without persistent spike protein, which would lead to additional oxidative stress in the heart. A Swiss study analyzed troponin levels in 777 hospital employees who received a booster injection after previously receiving two doses. On the third day after the booster, troponin levels above the upper limit of normal were observed in 2.8% of the subjects. By the next day, half of the elevated troponin levels had returned to the normal range. 119 While longer-term follow-up data were not available, this data presents some serious questions: What would the troponin levels have been at one day post-injection? Did the troponin levels, which were still elevated at day four post-in-

Source page 160

Open original page 160 — full-size image

160 THE ONLY CAUSE OF DISEASE

jection, ever completely return to normal? If so, how long did that take to occur? Rather than being concerned that some myocardial damage was caused by the vaccine, which is openly acknowledged in the study, it is dismissed as being of no importance since half of the elevated troponins resolved within 24 hours.

Any vaccine should not require or invoke any de- gree of damage to any tissue in the body, much less the heart, to stimulate an immune reaction to the antigenic material being injected. Additionally, as is often seen with many papers addressing related issues, the significance of any vaccine side effect is consistently downplayed, falsely concluding that the vaccine does much more good than harm without further qualification as to why such a conclusion is valid.

Having even the most minimal elevation of troponin not only raises the concern of some collective long-term heart damage, or the ease of having a “re-flaring” of inflammation with new spike protein exposures, as from a booster shot, but it also raises the concern of electrical instability in some of the inflamed myocardial cells. There is always a possibility of electrical instability in any inflamed myocardial muscle cells, as it is their normal physiological nature to transmit electrical impulses from one cell to the next. Because of this, stressful events that release surges of adrenaline and catechol- amines in the circulation, as is seen with peak physical exertion, can readily provoke such electrically unstable cells into precipitating and sustaining an abnormal heart rhythm. However, regardless of any benefits a COVID vaccine might have on the overall morbidity and mortality of those receiving it, it completely ignores that many effective treatments have been shown to either prevent most cases of COVID or to readily cure them when applied properly after the infection has been contracted. 120-124


Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Chapter 5 — How Toxins Cause Heart Failure

The Only Cause of Disease: Healing by Reversing Pathology — Thomas E. Levy, MD, JD

Part 4 of 7; physical source pages 161–166.

Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Unchanged original PDF


Source page 161

Open original page 161 — full-size image

How Introduction Toxins Cause Heart Failure 161

With the availability of effective treatments, no significant vaccine side effect, especially fatal ones, should ever be tolerated, unless the vaccine candidate is fully aware of all possible side effects and chooses not to be bothered with the simple measures proven to prevent and/or treat the infection for which the vaccine is being offered.

To date, every vaccine that has ever existed has a significant side effect profile. This information, along with a full disclosure of effective non-pharmaceutical therapies for the condition the vaccine is intended to prevent, should always be provided to both physi- cians and their patients. It is also important to recognize that most tissues and organs in the body lack reliable laboratory markers indicating the presence and extent of ongoing spike protein damage. Tracking heart damage with troponin levels makes this organ relatively unique in this regard. Since ACE2 receptors are present in most organs and tissues, any continued elevation of troponin can also be consid- ered a reliable indicator that spike protein damage is continuing to occur in organs and tissues outside of the heart. Spike protein would be expected to bind ACE2 receptors wherever it finds them, and such binding would always be expected to cause cellular inflam- mation and damage. Blood testing for natriuretic peptides also reflects myocardial damage. Still, the primary focus should remain on troponin testing and taking any necessary steps to return the test to the normal range and maintain it there. 125-131 PSP syndrome routinely involves the heart, even when not readily apparent clinically. The spike protein has such a strong affinity for the heart muscle that chronic COVID-19 or post-vacci- nation patients are unlikely to ever have spike protein or its patho- logical impact elsewhere in the body, while sparing the heart. In autopsies of patients who died of COVID-19, either COVID-related viral RNA or evidence of myocardial inflammation was seen more

Source page 162

Open original page 162 — full-size image

162 THE ONLY CAUSE OF DISEASE

than 80% of the time. 132 Another autopsy study on COVID-19 patients who expired revealed the presence of spike protein in the heart in over 60% of cases. 133 Clinically significant myocar- ditis developed from PSP can often If the absence of be missed and completely unsus- these causes is not pected clinically due to the patchy and clearly established, limited nature of many cases of spike prophylactic nutrient protein myocarditis. 134 The amount chelation should of heart tissue can often be so limited always be part of any that troponin levels remain unaffected, and even in the low normal range. In a therapeutic protocol, case report, conduction system cells in or the reversibility the atrioventricular (AV) node (heart of clinical heart cells that modulate the transmission failure will never be of the electrical signal to contracting realized. heart cells) were selectively inflamed, providing a reason why even a minimal, undetected spike protein myocar- ditis can trigger lethal arrhythmias. 135-136 In another case report, the spike protein was most dominant in the heart, specifically in the AV node and the pacemaker cells of the atrium. Scattered throughout the heart were single necrotic (dead) heart cells, adjacent to viable cells, further underscoring the exceptionally focal nature of spike protein attack in some patients. 137 Another autopsy study also reported this single-cell death in COVID hearts. 138-139 Unlike the other toxic cardiomyopathies, spike protein involve- ment in the heart is typically not generalized, but rather demon- strates scattered and minimal involvement of the heart muscle. 140 Nevertheless, sudden cardiac death (not from a heart attack due to “traditional” coronary atherosclerosis) is no longer uncommon, and persistent spike protein presence is impacting a large number of individuals around the world who are cardiac symptom-free

Source page 163

Open original page 163 — full-size image

How Introduction Toxins Cause Heart Failure 163

but still liable to life-threatening arrhythmias under conditions of stress, including previously otherwise healthy young athletes. 141 As the number of people with undetected spike protein/ COVID myocarditis is enormous already and steadily increasing, part of the therapy for anyone felt to have persistent spike protein should still involve the regular administration of one or more heavy metal chelation agents. As discussed above, heavy metals appear to “await” the microenvironment of myocardial inflam- mation of a previous viral infection to begin accumulating, if they have not already accumulated there before the COVID infection or the vaccine administration. As with all other toxins, the combina- tion of heavy metals and PSP will always substantially worsen any inflammation and electrical instability than from either one alone. Furthermore, this worsening is synergistic, and not just an additive negative impact of spike protein and heavy metals.

Before the diagnosis of idiopathic (unknown origin) cardiomyopathy is made, toxic and infectious causes must be ruled out. If the absence of these causes is not clearly established, prophylactic nutrient chelation should always be part of any therapeutic protocol, or the reversibility of clinical heart failure will never be realized. Currently, such diagnostic and therapeutic efforts are rarely made. 142

Spike Protein, Heart Block, and Pilots As would be logically expected, any agent that can cause inflammation in the heart would also be expected sometimes to involve the cells in the heart that generate and conduct the elec- trical sparks that initiate all contractions of the heart. As spike protein myocarditis can be patchy and not uniformly affect all heart muscle cells, heart rhythm problems are not always part of the clinical presentation of myocarditis. Nevertheless, when the

Source page 164

Open original page 164 — full-size image

164 THE ONLY CAUSE OF DISEASE

patchy involvement of heart cells involves some cells actively engaged in generating and conducting the electrical impulses that result in ventricular contraction, the presence of spike protein in only a few heart cells can still generate potentially fatal arrhyth- mias. Various degrees of heart block due to spike protein have been reported because of PSP. 143-148 A condition known as multisystem inflammatory syndrome in children (MIS-C) has emerged since the onset of the COVID pandemic, appearing primarily in advanced COVID infec- tions. 149-150 MIS-C and MIS in adults indicate that the COVID infection has resulted in widespread inflammation throughout the body, mostly developing from PSP, and often involving the heart and lungs. Minimal to advanced heartbeat conduction problems have occurred secondary to MIS-C, ranging from a prolonged PR interval (see below) on the electrocardiogram (ECG) to advanced and potentially life-threatening degrees of AV block. 151-152 When heart function is normal, the AV node allows a rapid conduc- tion of the electrical pulse received from the atrium throughout the heart in a near-simultaneous manner so that heart muscle contraction is synchronized and optimally efficient. AV block results in an abnormal slowing of the heart rate and sometimes fatal secondary arrhythmias, including complete stoppage of the heartbeat (asystole). The spike protein can damage the heart at any age, although certain patient groups are more susceptible to this than others. The PR interval is the time between atrial depolarization (contraction) and ventricular depolarization (contraction) as they pass through the atrioventricular node (AV node). Disease of the AV node, which affects its ability to optimally regulate impulse conduction leading to ventricular contraction, is reflected in the prolongation of this interval on the ECG. The normal PR interval ranges from 0.12 to 0.2 second. In younger individuals, especially well-trained athletes, a PR interval greater than 0.2 is usually

Source page 165

Open original page 165 — full-size image

How Introduction Toxins Cause Heart Failure 165

completely normal. However, when PR interval measurements have always been 0.2 or less and then start to lengthen as an older adult, there should be significant concern that the aging conduction system might manifest more significant conduction abnormali- ties in the future. In the context of the pandemic, it is particularly concerning when PR interval prolongation is observed for the first time following a bout of COVID-19 and/or vaccination. This is a clear indicator of new inf lammation in at least some of the heart conduction cells, however minimal it may be. Regardless, it should never be disregarded as inconsequential. All diseases have a spectrum of pathology, and the earliest stages of pathology should never be trivialized, especially when PSP might be present in the heart. 153

In a Harvard study that extended over a 30- to 40- year period, it was found that individuals with PR intervals greater than 0.2 second had twice the risk of atrial fibrillation, three times the risk of needing a pacemaker (meaning the presence of advanced degrees of heart block), and nearly a one=and=a=half times increase in all-cause mortality. Furthermore, greater degrees of PR interval prolongation were associated with an even greater risk of these out- comes. 154

However, ignoring the inherent pathology in “suddenly” prolonged PR intervals in the middle of a pandemic is precisely what the Federal Aviation Administration (FAA) appears to have done. Facing a shortage of pilots due to both the vaccine requirement it initiated during the pandemic for pilots to fly, along with many early retirements that resulted, the FAA decided to change the rules, disregarding long- standing parameters of normalcy based on medical science, rather than satisfying corporate or political convenience.

Source page 166

Open original page 166 — full-size image

166 THE ONLY CAUSE OF DISEASE

The FAA has now declared a PR interval of 0.3 second to be the upper limit of a “new normal” in the FAA Guide for Aviation Medical Examiners as of October 2022. The October 2021 standards stated that the PR interval was normal when it was 0.2 second or less. However, this was changed the following year without explanation. The only logical explanation is that many pilots had developed prolonged PR intervals on their ECGs, lasting longer than 0.2 second. But with the new “declaration” of normalcy, pilots who had no symptoms were able to obtain clearance to fly with a PR interval of 0.3 second or less. And when that interval was even greater than 0.3 second, a “current Holter and cardiac evaluation” was finally required to receive clear- ance to fly. Considering that the normal PR interval ranges between 0.12 and 0.20 second, an interval of 0.3 second represents a “permissible” increase in this interval by over 100% relative to the low normal interval of 0.12 second. This is not a nominal increase in the PR interval, but a substantial one.

When such PR interval prolongations are present and the Holter monitor test reveals a significant number of ectopic beats, vigorous magnesium supplementa- tion must be administered until the Holter test re- turns to a normal or very near-normal status, before a pilot is again permitted to fly (see Chapter 13).

Even now, a treadmill exercise stress test is not required for commercial pilots to receive medical clearance to f ly! This is not a safe policy by the FAA and arguably a shocking one, as many pilots are in the age range when heart attacks occur without any early symptoms, and still with a normal ECG, the ECG being the only mandatory heart-related test. Roughly a third of all deaths around the world are due to cardiovascular disease. And in Western countries, sudden


Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Chapter 5 — How Toxins Cause Heart Failure

The Only Cause of Disease: Healing by Reversing Pathology — Thomas E. Levy, MD, JD

Part 5 of 7; physical source pages 167–172.

Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Unchanged original PDF


Source page 167

Open original page 167 — full-size image

How Introduction Toxins Cause Heart Failure 167

cardiac death occurs in about half of all coronary artery disease patients. 155-156 More rigorous cardiac evaluations should be performed in prospective pilots and repeated at appropriate intervals. A normal ECG means a heart attack has not yet occurred, nothing more. A fatal heart attack from very advanced coronary artery disease could happen 10 minutes after a normal ECG was recorded. In addition to an ECG, all pilots should routinely have troponin and D-dimer levels measured. No pilot should ever fly when there is a persistent elevation of troponin levels and/or D-dimer levels, regardless of whether there are no apparent related symptoms. It is irrelevant that the pilot may feel well, have a normal ECG, and show no clinical evidence of myocarditis after having had COVID-19 or received a COVID-19 vaccination, without further testing, especially if the PR interval is greater than 0.2 second. As mentioned in Chapter 13, over 2,000 seemingly healthy young individuals, mostly European soccer players, have collapsed on the field of play from 2021 through 2023. About 1,400 of them died. This did not occur at all before the pandemic and the wide- spread COVID-19 vaccinations. These facts indicate how healthy a spike protein-compromised heart can appear before suddenly proceeding to a fatal arrhythmia. Similarly, any pilot who has had COVID and/or had one or more COVID vaccinations, and who has not been adequately eval- uated for unsuspected signs of PSP, can potentially experience a life-threatening arrhythmia when a significant stress-provoking emergency arises in the cockpit. And if there are some underlying inflamed heart cells, for both pilots and athletes, these factors can increase the risk of a catastrophic arrhythmia: ✓ ECG finding of early repolarization ✓ Consumption of caffeine, alcohol, or stimulant drinks

Source page 168

Open original page 168 — full-size image

168 THE ONLY CAUSE OF DISEASE

✓ Consumption of water in plastic bottles (increased antimony exposure) ✓ Increased systemic inflammation and circulating toxins ✓ Surges of adrenaline during high- exercise or high-stress moments ✓ Moments of decreased oxygen tension (hypoxia) at peak exercise or chronically lower oxygen levels at altitude in the plane ✓ An abnormal lengthening of the PR interval on the ECG during the pandemic, after having been normal for the entire life up to that point ✓ Genetic or acquired structural abnormalities in the physical structure of the heart predisposed to starting and sustaining arrhythmias (reentry pathways) ✓ Underlying congestive or hypertrophic cardiomyopathy, with heart wall thickening and/ or heart chamber dilation, usually with significant heavy metal accumulation in the heart cells ✓ Chronically low mitochondrial magnesium levels in the heart cells (further aggravated by sweating and diuretics). This is the primary factor that must be present to initiate extra beats and sustained arrhythmias in the first place. The presence of early repolarization on an ECG is an inter- esting risk factor for cardiac arrhythmia, as it is considered a normal finding in younger individuals up to the age of 40 to 50. Yet, it can still be a factor that helps trigger an arrhythmia when inflamed conduction cells are present in the heart, as seen in PSP. The J wave (see diagram on next page) on the ECG represents a slightly skewed and prolonged QRS complex. This skewing of the depolarization phase of the ECG is a point in time when the heart is more readily provoked into generating an extra (ectopic) beat than during the

Source page 169

Open original page 169 — full-size image

How Introduction Toxins Cause Heart Failure 169

Q R S

The Q wave is the small dip down (negative wave) just prior to the large upward (positive wave), called the R wave, and the small negative wave after the R wave is called the S wave. The three waves as seen on an ECG are called the QRS complex. A J wave is an aberrant prolongation of the QRS complex and might indicate a heart that is prone to ectopic beats.

classically normal and tightly synchronous QRS complex seen in older individuals without heart disease. 157 It has been established that PSP myocarditis following vaccination is most common in young men. 158 Furthermore, sudden cardiac death secondary to PSP myocarditis has appeared to target the young (<40) substantially more often than even older individuals with one or more chronic diseases. While counterintui- tive, there is a good explanation. Statistically, the presence of early repolarization with J waves is seen in 1% to 13% of the general population, although it is signifi- cantly more common in athletes. 159 Most young individuals with this condition eventually lose it as they age. It is described as an imbalance between the epicardial and endocardial heart muscle layers, characterized by increased dispersion, or spreading out, of depolarization and repolarization. 160 By itself, however, when there is no inflammation (PSP) working to destabilize cardiac conduction cells, early repolarization has been well-established to be a benign

Source page 170

Open original page 170 — full-size image

170 THE ONLY CAUSE OF DISEASE

ECG normal variant with no correlation to an increased incidence of hospitalization. 161-162 This means that early repolarization alone is of no concern, but it can combine with other risk factors to increase the chances of significant arrhythmia. 163 In other words, early repolarization represents an electrical sequence in the conduc- tive pathways of the heart that only becomes unstable when other pro-arrhythmic factors (such as decreased intracellular magnesium levels) are present as well. Nevertheless, in patients with “sudden death” arrhythmias like ventricular fibrillation, early repolarization with J waves was seen six times more commonly than in control subjects (31% vs. 5%). In eight individuals, the origin of the extra beats provoking the arrhythmia was electrophysiologically mapped to sites associated with the origin of the J waves. 164

Spike Protein and Blood Clotting A D-dimer blood test is a measure of the degree to which blood clots that have already formed are breaking up (lysis) and releasing those breakdown products into the blood. It is not a direct measure of how prone the blood is to clotting in the first place (increased coagulability). However, it is a very sensitive test that will always be elevated when increased blood clotting is occurring, since those clots must still be broken down to prevent circulation from shutting down. An elevated D-dimer test should always raise concern, as it indicates that increased blood clotting is almost certainly occurring. Only rarely is significant thrombosis seen in the absence of an elevated D-dimer level. 165 In the context of the pandemic, individuals with a history of acute or chronic COVID-19 infection, as well as those who have received one or more vaccinations, should always be concerned if their D-dimer test results are elevated. It is clear evidence that there is an ongoing presence of spike protein binding to ACE2 receptors

Source page 171

Open original page 171 — full-size image

How Introduction Toxins Cause Heart Failure 171

in the inner lining (endothelium) of blood vessels in the body and/ or to circulating platelets themselves, which initiates the forma- tion of blood clots. Both contribute directly to blood clotting. 166 Blood clots can range from microscopic to massive. Such clotting is not typically part of a non-pandemic myocarditis free An elevated of spike protein. Certainly, having both D-dimer test elevated troponin levels and elevated should always D-dimer levels is especially worrisome and raise concern, as warrants prompt and aggressive treatment it indicates that to resolve the underlying pathology. increased blood Both the COVID-19 vaccine and clotting is almost the COVID-19 infection have been certainly occurring. documented to cause increased blood clotting and thrombosis. 167 Viral infec- tions, in general, have also been found to promote abnormal blood clotting. 168 In critically ill hospitalized COVID patients, elevated D-dimer levels were found in about 60% of the time. 169 Not surpris- ingly, the longer that D-dimer levels remain elevated in COVID patients, the greater the morbidity and mortality. 170-172 Similarly, the higher the D-dimer level on hospital admission for COVID, the greater the chances of in-hospital mortality. 173 When the underlying infection or other pathology is resolved, D-dimer levels can be expected to decrease as well. If a throm- botic event occurs, resolves, and there is no ongoing underlying pathology, D-dimer elevations will generally persist for only a few days before returning to normal. However, chronic COVID infec- tions often demonstrate persistent blood clotting problems. In one study, 25% of a recuperating group of COVID-19 patients, who were already four months past the acute clinical phase of their infec- tions, still demonstrated increased D-dimer levels. Additionally, the other standard laboratory parameters of blood clotting had already returned to normal in over 90% of these patients, indicating the

Source page 172

Open original page 172 — full-size image

172 THE ONLY CAUSE OF DISEASE

increased sensitivity of D-dimer testing in detecting blood clotting pathology. These additional tests included prothrombin time, partial thromboplastin time, fibrinogen levels, and platelet count. Even C-reactive protein and interleukin-6, tests that track inflam- mation, had typically also returned to normal. 174 Platelet levels generally drop in the blood at the same time D-dimer levels are increasing, as they are consumed in the forma- tion of the blood clots. 175 A post-COVID vaccination syndrome, known as vaccine-induced prothrombotic immune thrombo- cytopenia (VIPIT), with these laboratory findings, has been described. 176-179 While the pandemic has given more attention to D-dimer testing than it ever had before, a D-dimer elevation can also be seen in a limited number of other conditions. 180 However, anyone today who is not chronically ill but still found to have an elevation of their D-dimer levels is likely suffering from the consequences of PSP presence in their vasculature, whether due to lingering COVID infection or due to having received one or more COVID vaccina- tions. Even if an individual has never had COVID or received a vaccination, an extensive medical evaluation is always warranted, as a D-dimer elevation is never normal. A persistently elevated D-dimer level should never be dismissed as inconsequential just because the patient feels well. Notably, a PSP presence can be detected in many tissues despite being cleared from the blood, resulting in a chronic COVID-19 picture in that patient, despite a normal D-dimer level. Chronic COVID-19 with spike protein in the blood, resulting in an elevated D-dimer, always has a worse long-term prognosis than when it is absent from the blood with a normal D-dimer level. Aside from inducing fatal arrhythmias, PSP will generally only kill because of thrombotic complications.


Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Chapter 5 — How Toxins Cause Heart Failure

The Only Cause of Disease: Healing by Reversing Pathology — Thomas E. Levy, MD, JD

Part 6 of 7; physical source pages 173–178.

Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Unchanged original PDF


Source page 173

Open original page 173 — full-size image

How Introduction Toxins Cause Heart Failure 173

ATP Physiology and Cardiomyopathy No cell, whether in the heart or elsewhere, is healthy when mitochondrial function and ATP production are chronically suppressed. Such suppression will reliably occur when the reduc- tion-oxidation balance inside the cells is sufficiently shifted toward excess oxidation. All diseased cells have an insufficient presence of antioxidants, which is reflected in higher cellular levels of calcium and lower cellular levels of magnesium, vitamin C, and glutathione. When these levels remain low, mitochondrial ATP production will also be depressed. These cellular abnormalities are consistently present in diseased tissues or organs. 181-182 When cardiac ATP production can be restored to optimal levels, accompanied by a normal ability to increase with exercise, a healthy heart will result, unless irreversible damage has already occurred. Of note, mitochondria are especially abundant in heart tissue, and these mitochondria generate more than 90% of the heart’s energy. As the heart seeks to renew its ATP content every 20 seconds or so, it can demonstrate clear mitochondrial insuffi- ciency (heart failure) when other organs appear to be less affected or completely unaffected. 183-184 No organ consumes more energy per gram of tissue than the heart. 185 As the mitochondria are the intracellular sites of ATP (energy) production, significant research has been directed at finding ways to reverse or lessen “mitochondrial dysfunction.” 186 In most cases, mitochondrial dysfunction evolves from the increased oxidative stress resulting from chronic infection and toxin accumulation. However, rare genetic defects in mitochondrial function can also result in a similar clinical picture, characterized by decreased energy production. 187 Much of this mitochondrial research has focused on defects in the electron transport chain (ETC), which is embedded in the membranes of the mitochondria. The ETC directly fuels the ATP synthase enzyme, which is vital to the production of ATP at the

Source page 174

Open original page 174 — full-size image

174 THE ONLY CAUSE OF DISEASE

end of the chain. The ETC has four main complexes, or steps, that work to optimally shuttle electrons to the terminal ATP-producing enzyme. 188-189 These complexes and their significant characteristics can be summarized and greatly simplified as follows: ✓ Complex I: NAD (nicotinamide adenine dinucleotide) in its reduced form, NADH, starts the electron donation sequence. ✓ Complex II: FAD (flavin adenine dinucleotide) in its reduced form, FADH2, continues the electron relay to ubiquinone (oxidized coenzyme Q10 [CoQ10]). ✓ Complex III: Ubiquinol (reduced CoQ10) relays the electrons to cytochrome c. ✓ Complex IV: Cytochrome c oxidase then receives the electrons, where molecular oxygen is bound and reduced to water. ✓ ATP synthase (sometimes known as complex V) is then activated to complete the ETC electron shuttling with the subsequent production of ATP. Mitochondrial dysfunction is most successfully addressed when the substrates of the ETC (NAD, FAD, CoQ10) are either directly supplemented or the precursors needed for their synthesis are supplemented. Fueling the ETC not only produces more ATP, but it also results in less oxidative stress being generated by the ETC agents as mitochondrial function becomes more efficient and total cellular oxidation declines. 190-191 When ATP can be increased and oxidative stress can be decreased, mitochondrial healing can occur. Such healing is suggested in a study that found cardiovascular mortality to remain reduced for eight years following the comple- tion of four years of supplementation with CoQ10 and selenium. 192 Defects in the ETC have been specifically identified in heart failure and are always present. 193 In even the most advanced cases of heart failure, there are still inflamed but viable heart cells that can be positively impacted with improved ATP production. Aside

Source page 175

Open original page 175 — full-size image

How Introduction Toxins Cause Heart Failure 175

from the chelation therapies noted above, bolstering mitochondrial function has been a primary physiological goal in the treatment of heart failure. 194 While heart disease can occur from inherited mito- chondrial disorders, most cases of heart failure are due to diseased mitochondria because of the pathogens and accumulated toxins in the heart. 195 Traditional medicine has no drugs that directly work to normalize mitochondrial dysfunction in heart failure patients. Instead, all the current prescription drugs work only to mobilize excess fluid accumulations and/or to lessen the workload (periph- eral resistance) faced by the failing heart muscle. This is not to say that there is no place for these drugs, only that they should not be the only agents given to the patient. As with most prescription drugs, the therapeutic goal appears limited to symptom improve- ment while letting the underlying pathology continue to evolve. Traditional medicine is much better at diagnosing and naming medical conditions than at reversing or resolving them.

When targeted therapies capable of entering the ETC of the mitochondria and improving ATP pro- duction are utilized, the clinical response in heart failure is often dramatic. These include many of the patients considered to have terminal congestive cardio- myopathies with no possibility of improvement or signif- icant long-term survival without heart transplantation.

CoQ10 is the most researched of these ETC-targeted therapies for cardiomyopathy, and its enormous benefits on cardiac function have been well-documented. The especially vital role of CoQ10 in supporting ATP production in the heart is reflected in its concen- trations in different tissues in the body. Far more CoQ10 is found in the heart than is found in any of the 12 other human tissues examined. Furthermore, the heart contained roughly twice as much CoQ10 as the kidneys, the organ/tissue with the second-highest

Source page 176

Open original page 176 — full-size image

176 THE ONLY CAUSE OF DISEASE

CoQ10 concentrations in the study. Non-cardiac muscle had only one-third of the CoQ10 of the heart muscle. 196 CoQ10 also promotes the function of the mitochondrial ETC by supporting the electron transfer in complexes I and II, as well as by its established role in complex III. Its impact in restoring heart function in cardiomyopathy has been significant and some- times stunning, especially since this is a condition that is only given supportive care by traditional cardiologists who appear to remain unaware of this highly therapeutic nutritional supplement, even in the face of solid scientific data in the medical literature. In a randomized, double-blind trial in 420 patients with severe heart failure, and followed for two years, there was a 42% reduc- tion in all-cause mortality and cardiac mortality in patients given 100 mg of In a randomized, CoQ10 three times daily. Fewer hospi- double-blind trial in talizations for heart failure occurred 420 patients with in the treated group as well. 197 The severe heart failure, supplementation of selenium along and followed for with CoQ10 appears to be especially two years, there was effective in reducing mortality in cardiomyopathy patients. 198 a 42% reduction in all-cause The ejection fraction (EF), a mortality and measure of how effectively the heart contracts and empties with each beat, is cardiac mortality in the most objective and readily measur- patients given 100 able parameter for evaluating cardiac mg of CoQ10 three function. EFs considered to be normal times daily. run roughly from 65% to 80%. Many sources consider 50% to 70% to be the normal range. However, EFs in the 50% vicinity are already demon- strating a significant loss of cardiac function, even though enough cardiac function is present to meet the demands of the typical older

Source page 177

Open original page 177 — full-size image

How Introduction Toxins Cause Heart Failure 177

lifestyle. EFs of 10% to 15% represent the most significant loss of cardiac function and are characteristic numbers for patients with massive heart enlargement on heart transplant waiting lists. CoQ10 supplementation has rescued many patients considered to have terminal heart failure, and this has been accompanied by dramatic improvements in EF and functional capacity in most patients, with one study showing the mean EF going from 25% to 42%. 199-204 It should also be noted that increasing an EF from 15% to 25% can transform a patient who has difficulty walking across the room without shortness of breath into one who can function normally, as long as major physical stresses are avoided. The initial pathology seen in the heart failure of hypertrophic cardiomyopathy with preserved EFs is also clearly improved with CoQ10 supplementation. 205-206 Low CoQ10 levels, along with increased CRP (C-reactive protein, a marker of oxidative stress) levels, have been documented in heart failure, whether due to coronary disease or of unknown cause. 207 Other studies have also shown that lower CoQ10 serum levels correlated with increased all-cause mortality in general, as well as in heart failure patients. 208-209 Conversely, CoQ10 supplementation has been shown to decrease all-cause mortality in all subjects. Furthermore, CoQ10 supplementation has been shown to increase exercise capacity in patients with heart failure, with no significant adverse effects or safety issues reported. 210-213 First discovered in 1955, the benefits of CoQ10 in heart failure have been extensively documented in the scientific literature for over 50 years. Yet, established textbooks of medicine and medical therapeutic manuals make no mention of this vital nutrient antioxidant, let alone its impact on congestive heart failure. 214-218

Source page 178

Open original page 178 — full-size image

178 THE ONLY CAUSE OF DISEASE

As CoQ10 increases energy production in all cells of the body, it should not be surprising that studies have shown its benefits in a wide variety of diseases. Low levels have been docu- mented in many medical conditions, along with evidence of its clear benefits when administered properly or supplemented. Such conditions include the following: ✓ Brain disorders, including Parkinson’s disease, Alzheimer’s disease, stroke, and depression 219-222 ✓ Autism 223 ✓ ADHD (Attention Deficit Hyperactivity Disorder) 224 ✓ Hypertension (high blood pressure) 225-228 ✓ Coronary artery disease (atherosclerosis) and acute myocardial infarction 229-232 ✓ Improved clinical outcome post-coronary bypass and post-coronary angioplasty 233-234 ✓ Atrial fibrillation 235 ✓ Asthma 236-237 ✓ Obesity 238 ✓ Fibromyalgia 239 ✓ Diabetes (improved glucose and lipid profile) 240 ✓ Multiorgan failure when genetically deficient 241 ✓ Improvement in chronic kidney disease 242 ✓ Chronic lung disease 243 ✓ Fatty liver disease 244 ✓ Chronically increased oxidative stress 245 ✓ Vertigo 246 ✓ Sepsis and any critical illness 247-249 ✓ Statin cardiomyopathy 250 ✓ Statin myopathy (skeletal )251 ✓ Eye disease 252


Book introduction and complete contents · Previous section · Next section · Previous part · Next part

Chapter 5 — How Toxins Cause Heart Failure

The Only Cause of Disease: Healing by Reversing Pathology — Thomas E. Levy, MD, JD

Part 7 of 7; physical source pages 179–182.

Book introduction and complete contents · Previous section · Next section · Previous part

Unchanged original PDF


Source page 179

Open original page 179 — full-size image

How Introduction Toxins Cause Heart Failure 179

As CoQ10 is one of the few vital antioxidants that the body synthesizes, aging accounts for much of its deficiency. Older people typically produce less CoQ10, generally have a lower dietary intake of it, and often have other medical conditions that necessitate a higher consumption of it. The average 80-year-old has approxi- mately 50% of the cardiac CoQ10 content compared to the average 20-year-old. 253-254 But its importance in cardiac function is the same regardless of age. Just as deficient hormone levels need to be restored to optimize health in the aging patient, CoQ10 also needs to be addressed, as it is essential for the optimal health of all cells. 255 Additional supplementation can specifically target complexes I, II, and IV in the mitochondrial ETC to help optimize ATP production. Not only will such supplementation be beneficial to all cells of the body, but the increased ATP demands of the heart make them especially suited to help support and improve the function of a failing heart. 256 NAD (nicotinamide adenine dinucleotide) is the primary substrate fueling complex I. The primary way to keep NAD levels high, in addition to directly supplementing NAD itself, is to take large amounts of its primary precursor for being synthesized in the body. This role is served by niacin (vitamin B3) and its vitamers (like niacinamide). 257 Levels of both NAD and ATP have been documented to be significantly depressed in cardiomyopathy biopsy specimens. 258 Like CoQ10, niacin significantly improves all cardiovascular conditions, not just cardiomyopathy. 259-269 A severe niacin deficiency state has also been documented to be the root pathology in schizophrenia and other brain disorders, consistent with the high ATP requirements of the central nervous system for normal function. 270 Severe niacin deficiency results in pellagra, a life-threatening condition that is also associated with diminished heart contractility. 271-273

Source page 180

Open original page 180 — full-size image

180 THE ONLY CAUSE OF DISEASE

Riboflavin (vitamin B2) also plays a critical role in optimizing mitochondrial ATP production. It serves as a precursor, or building block, for FAD, the electron-transferring substrate in complex II of the ETC. 274 An animal study demonstrated that riboflavin can alleviate heart failure and improve cardiac metabolism. 275 It can also lessen the amount of damage that reduced blood flow, or ischemia, will inflict on the heart. 276 A genetic deficiency of complex II results in an advanced congestive cardiomyopathy, indi- cating its importance in this condition. 277 When FAD is targeted as an antigen by anti-mitochondrial antibodies, a dilated cardiomyop- athy results as well. 278 Complex IV of the ETC, involving the transfer of electrons via cytochrome c oxidase to oxygen, the terminal electron acceptor, is strongly supported by methylene blue (MB). 279 MB is a powerful redox agent that has been shown to benefit neurodegenerative diseases by increasing mitochondrial energy production. 280-283 Promoting ETC ATP production by directly supporting complex IV is especially significant since the obligatory oxidative stress generated in the first three complexes is avoided. This means that less net oxidative stress is generated in the cell without compro- mising ATP production, a rarely achieved therapeutic goal. 284 This effect is also why MB has been promoted as an anti-aging agent, as cumulative oxidative stress is a primary cause of all aspects of aging. 285 In cellular studies, MB delays the aging process. 286 Consistent with its documented brain benefits, MB has also been shown to protect and heal the heart. Well-documented to completely rescue and cure patients with refractory septic shock resistant to all other measures as a monotherapy, MB was also able to improve cardiac function in a septic shock patient who already had an advanced cardiomyopathy. 287-289 Other studies have consis- tently confirmed the positive effect of MB on septic shock. 290-291

Source page 181

Open original page 181 — full-size image

How Introduction Toxins Cause Heart Failure 181

Advanced states of hemodynamic shock without sepsis have also been resolved by MB treatment. 292 In animal studies, MB not only improves ETC energy production but also decreases oxidative stress and improves NAD levels in the mitochondria. 293-294

Recap The heart muscle in all cardiomyopathies is depleted in ATP, the most critical energy-producing molecule in the body. The worse the cardiomyopathy, the more severe the depletion. Nearly all the time, this ATP-depleted state is precipitated and main- tained by heavy metal accumulations, often accelerated by earlier pathogen-provoked myocardial inflammation (myocarditis). Such myocarditis is typically undetectable on routine laboratory tests, and only more invasive testing can confirm its presence.

When a patient presents with an enlarged, poorly contracting heart, it must be assumed that signif- icant heavy metal accumulations are present, and the treatment protocol must include chelation/toxin mobilization therapy.

Depending on the patient’s history and laboratory findings, the clinician must also determine whether chronic COVID-19 with persistent spike protein-mediated inflammation is a significant (or a major part of) the underlying pathology. If this is confirmed, or if clinical suspicions are high, measures to eradicate the spike protein should be vigorously pursued. In addition to the heavy metal/toxin removal measures, targeted supplementation designed to directly support and heal the failing ability of the cardiac mitochondria to produce normal levels of ATP is essential for an optimal cardiac and clinical response. This supplementation will be discussed in Chapter 18.

Source page 182

Open original page 182 — full-size image

182 THE ONLY CAUSE OF DISEASE

Even if there is a refusal to acknowledge the likely presence of heavy metals in the failing heart muscle, which will continue to be the rule rather than the exception among traditional cardiologists, nontoxic non-prescription nutrient chelators and ATP pro- duction promoters can still be taken as desired, and substantial benefit can still be anticipated.


Book introduction and complete contents · Previous section · Next section · Previous part